HSBC Holdings’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

HSBC Holdings’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-638,841	Closed	-$6.45M	–	3265
2022 Q4	$6.45M	Hold	638,841	–	–	0.01%	1148
2022 Q3	$6.34M	Buy	+638,841	New	+$6.31M	0.01%	1083

HSBC Holdings's BIOT Position: Q1 2023 in Review

HSBC Holdings sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 638,841 shares — an estimated $6.45M sold.

HSBC Holdings first reported a position in BIOT in Q3 2022 and held it in 2 quarters. The position peaked at $6.45M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

HSBC Holdings reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
HSBC Holdings sold 638,841 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $6.45M.
HSBC Holdings first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q3 2022 and held it in 2 quarters.
HSBC Holdings's Biotech Acquisition Company Class A Ordinary Shares position peaked at $6.45M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on HSBC Holdings's 13F filing for Q1 2023, filed 15 May 2023.